Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer.
about
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serumGenome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogueERβ-mediated estradiol enhances epithelial mesenchymal transition of lung adenocarcinoma through increasing transcription of midkine.Midkine expression in high grade gliomas: Correlation of this novel marker with proliferation and survival in human gliomas.Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cellsOptimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Multianalyte assay systems in the differential diagnosis of ovarian cancer.Stage-specific analysis of plasma protein profiles in ovarian cancer: Difference in-gel electrophoresis analysis of pooled clinical samples.Biomarkers for early detection of ovarian cancer.Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.A multiplex platform for the identification of ovarian cancer biomarkersMidkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.Diagnostic and predictive role of cell-free midkine in malignant pleural effusions.Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine.Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.
P2860
Q24307894-7B7E1EFA-381C-44B4-AC08-E4FF78121308Q28541775-6C67363C-6591-4E36-AA06-C658456A7269Q33636340-2E826016-508F-487F-8BD6-CCB187B9F8ADQ33771116-A75F99DC-5238-4015-A7BF-56B2E06A31D8Q34244781-D90AD833-F5F2-41B6-804A-DB6F4B92254DQ35402367-5BE86BB9-F954-4D49-B04E-18E62111FCC9Q35640277-CAA64423-686F-4708-8A71-B65A8B389C4CQ35837949-1BD110F3-CD61-4373-942B-9156979EBDD9Q35854476-3E4F91B4-BF71-40B1-AEBC-7B84838CE995Q37005879-978691D6-11BA-4CF5-BCE9-E7D7095389FAQ38087982-4AB23A80-0D22-4981-A211-6CEB27C67D4EQ38181600-7AC0E3C7-1DFF-458F-B0FB-881F715A7DF3Q42374131-01783674-D213-4E88-B9D3-F2DE8B5A742EQ44425656-AB621163-9750-4BD0-B234-3C5EAB5184C4Q44677297-EFE59B79-163D-4F03-A396-9C044E6F3D64Q44866906-7A422EC8-0315-404C-BC80-81EF83EF44A9Q46249379-31CF0B50-675E-4B98-83B5-A77FAC1DF8B3Q47898529-C2873EF9-353D-4D1E-ADD1-7004B7DD049D
P2860
Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of midkine and ante ...... e detection of ovarian cancer.
@ast
Evaluation of midkine and ante ...... e detection of ovarian cancer.
@en
type
label
Evaluation of midkine and ante ...... e detection of ovarian cancer.
@ast
Evaluation of midkine and ante ...... e detection of ovarian cancer.
@en
prefLabel
Evaluation of midkine and ante ...... e detection of ovarian cancer.
@ast
Evaluation of midkine and ante ...... e detection of ovarian cancer.
@en
P2860
P356
P1476
Evaluation of midkine and ante ...... he detection of ovarian cancer
@en
P2093
Dominic J Autelitano
P2860
P2888
P356
10.1186/1756-9966-29-62
P577
2010-06-03T00:00:00Z
P5875
P6179
1009704349